Jci_page_head_homepage_01 Jci_page_head_homepage_02
Tae-Il Jeon, Bing Zhu, Jarrod L. Larson, Timothy F. Osborne
Published in Volume 118, Issue 11
J Clin Invest. 2008; 118(11):3693–3700 doi:10.1172/JCI36461
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 3
SREBP-2 activates mT2R138 promoter in transient assays.

(A) 293T cells in 24-well microplates were cotransfected with –1,790 mT2R138 reporter and increasing amounts of the empty vector (pcDNA 3.1) or SREBP-2 expression construct as described in Methods, and the luciferase activities were normalized to β-gal activity. (B) 293T cells were cotransfected with a deletion series of T2R138 promoter constructs (–1,580 and –750) along with the empty vector or SREBP-2 expression construct (30 ng). Data are mean ± SEM; n = 3 for 5 separate experiments. (C) Purified recombinant SREBP-2 was used in an EMSA assay with 32P-labeled probe containing the putative SRE2 of mT2R138 promoter. Data are representative of 3 separate experiments. HMGCS, HMG Co-A synthase; LDLR, LDL receptor; Mt, mutant.